Emerging therapies in mantle cell lymphoma

Table 3 BiTes currently in trials

BiTe	NCT#/publication	Route/administration schedule	Phase	Sample size* [follow-up**]	Median lines of prior therapy	ORR% [CR%]	CRS [grade ≥ 3]	Neurotoxicity [grade ≥ 3]
Blinatumomab	NCT00274742 [95, 96]	IV continuous infusion over 4 or 8 weeks	I	24 [5.2]	3	71.1^a [42.8]	NP [NP]	71 [22]
Mosunetuzumab	NCT02500407 [97]	IV once every 21 days	I/Ib	23 [NP]	3	NP [NP]	28.9 [1.4]	43.7 [3.2]
REGN1979	NCT03888105 [98]	IV weekly for 12 weeks, then every 2 weeks for 24 weeks	I	6 [NP]	3	NP [NP]	57 [7.2]	NP [3.1]
GEN3013	NCT03625037 [99]	Subcutaneous weekly: cycle 1–2; every 2 weeks cycle 3-6; every 28 days thereafter	I/II	NP	3	NP [NP]	50 [0]	0 [0]

Abbreviations: NR not reached, NP not presented, ORR overall response rate, CR complete response, PFS progression-free survival, CRS cytokine release syndrome
^aResponse rate at the target dose of ≥ 60 ug/m²/day (n = 7 MCL patients)
*The sample size denotes only MCL patients
**f/up in months

ISSN: 1756-8722